Gen-Probe outside Roche, Chugai merger
This article was originally published in Clinica
Chugai Pharmaceutical's US diagnostics and blood screening unit, Gen-Probe, is to be spun off following the Tokyo company's acquisition by Switzerland's Roche Holding. The purchase of a majority holding in Chugai, announced last week, is expected to be completed by the last quarter of 2002 year, says Roche, whereafter Nippon Roche and Chugai will merge. The spin-off of San Diego-based Gen-Probe will take place prior to completion of the merger. Chugai will keep its name, but be known as a "member company of Roche".
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.